The Claim

In a subset of heart transplant recipients, PCSK9 inhibitor therapy is associated with stable coronary plaque thickness and lumen area over time, as assessed by serial coronary angiography and intravascular ultrasound imaging.

Source: PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
41score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

For some people who've had a heart transplant, taking PCSK9 inhibitor drugs might help keep the inside of their heart's blood vessels from getting narrower over time.

See the scientific wording

In a subset of heart transplant recipients, PCSK9 inhibitor therapy is associated with stable coronary plaque thickness and lumen area over time, as measured by serial coronary angiography and intravascular ultrasound.

What the research says

1 study

  1. Study: PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

    The study looked at PCSK9 inhibitors in heart transplant patients and found that in one group, the treatment was linked to stable heart artery plaque and vessel size over time, which matches the claim.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.